• Je něco špatně v tomto záznamu ?

Pulmonary Vein Isolation With Very High Power, Short Duration, Temperature-Controlled Lesions: The QDOT-FAST Trial

VY. Reddy, M. Grimaldi, T. De Potter, JM. Vijgen, A. Bulava, MF. Duytschaever, M. Martinek, A. Natale, S. Knecht, P. Neuzil, H. Pürerfellner,

. 2019 ; 5 (7) : 778-786. [pub] 20190508

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinická studie, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028886

OBJECTIVES: This study sought to evaluate the safety and short-term performance of a novel catheter for very high power-short duration (vHPSD) ablation in the treatment of paroxysmal atrial fibrillation. BACKGROUND: The vHPSD catheter is a novel contact force-sensing catheter optimized for temperature-controlled radiofrequency ablation with microelectrodes and 6 thermocouples for real-time temperature monitoring; the associated vHPSD algorithm modulates power to maintain target temperature during 90 W, 4 s lesions. METHODS: QDOT-FAST (Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation) is a prospective, multicenter, single-arm study enrolling patients with symptomatic paroxysmal atrial fibrillation indicated for catheter-based pulmonary vein isolation. Primary endpoints were short-term effectiveness (confirmation of entrance block in all targeted pulmonary veins after adenosine/isoproterenol challenge) and short-term safety (primary adverse events). Participants were screened for silent cerebral lesions by magnetic resonance imaging. Patients were followed for 3 months post-ablation. RESULTS: A total of 52 patients underwent ablation and completed follow-up. Pulmonary vein isolation was achieved in all patients using the study catheter alone, with total procedure and fluoroscopy times of 105.2 ± 24.7 min and 6.6 ± 8.2 min, respectively. Most patients (n = 49; 94.2%) were in sinus rhythm at 3 months. Two primary adverse events were reported: 1 pseudoaneurysm; and 1 asymptomatic thromboembolism. There were no deaths, stroke, atrioesophageal fistula, pulmonary vein stenosis, or unanticipated adverse device effects. Six patients had identified silent cerebral lesions-all classified as asymptomatic without clinical or neurologic deficits. CONCLUSIONS: This first-in-human study of a novel catheter with optimized temperature control demonstrated the clinical feasibility and safety of vHPSD ablation. Procedure and fluoroscopy times were substantially lower than historical standard ablation with point-by-point catheters. (Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation [QDOT-FAST]; NCT03459196).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028886
003      
CZ-PrNML
005      
20210304151930.0
007      
ta
008      
210105s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jacep.2019.04.009 $2 doi
035    __
$a (PubMed)31320006
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Reddy, Vivek Y $u Cardiac Electrophysiology, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic. Electronic address: vivek.reddy@mountsinai.org.
245    10
$a Pulmonary Vein Isolation With Very High Power, Short Duration, Temperature-Controlled Lesions: The QDOT-FAST Trial / $c VY. Reddy, M. Grimaldi, T. De Potter, JM. Vijgen, A. Bulava, MF. Duytschaever, M. Martinek, A. Natale, S. Knecht, P. Neuzil, H. Pürerfellner,
520    9_
$a OBJECTIVES: This study sought to evaluate the safety and short-term performance of a novel catheter for very high power-short duration (vHPSD) ablation in the treatment of paroxysmal atrial fibrillation. BACKGROUND: The vHPSD catheter is a novel contact force-sensing catheter optimized for temperature-controlled radiofrequency ablation with microelectrodes and 6 thermocouples for real-time temperature monitoring; the associated vHPSD algorithm modulates power to maintain target temperature during 90 W, 4 s lesions. METHODS: QDOT-FAST (Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation) is a prospective, multicenter, single-arm study enrolling patients with symptomatic paroxysmal atrial fibrillation indicated for catheter-based pulmonary vein isolation. Primary endpoints were short-term effectiveness (confirmation of entrance block in all targeted pulmonary veins after adenosine/isoproterenol challenge) and short-term safety (primary adverse events). Participants were screened for silent cerebral lesions by magnetic resonance imaging. Patients were followed for 3 months post-ablation. RESULTS: A total of 52 patients underwent ablation and completed follow-up. Pulmonary vein isolation was achieved in all patients using the study catheter alone, with total procedure and fluoroscopy times of 105.2 ± 24.7 min and 6.6 ± 8.2 min, respectively. Most patients (n = 49; 94.2%) were in sinus rhythm at 3 months. Two primary adverse events were reported: 1 pseudoaneurysm; and 1 asymptomatic thromboembolism. There were no deaths, stroke, atrioesophageal fistula, pulmonary vein stenosis, or unanticipated adverse device effects. Six patients had identified silent cerebral lesions-all classified as asymptomatic without clinical or neurologic deficits. CONCLUSIONS: This first-in-human study of a novel catheter with optimized temperature control demonstrated the clinical feasibility and safety of vHPSD ablation. Procedure and fluoroscopy times were substantially lower than historical standard ablation with point-by-point catheters. (Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation [QDOT-FAST]; NCT03459196).
650    _2
$a senioři $7 D000368
650    _2
$a fibrilace síní $x chirurgie $7 D001281
650    12
$a katetrizační ablace $x škodlivé účinky $x přístrojové vybavení $x metody $7 D017115
650    _2
$a katétry $x škodlivé účinky $7 D057785
650    _2
$a design vybavení $7 D004867
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluoroskopie $7 D005471
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikroelektrody $7 D008839
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a venae pulmonales $x chirurgie $7 D011667
650    _2
$a léčebná irigace $x přístrojové vybavení $7 D007507
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinická studie $7 D000068397
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Grimaldi, Massimo $u Department of Cardiology, Ospedale Generale Regionale F. Muilli, Acquaviva delle Fonti, Italy.
700    1_
$a De Potter, Tom $u Cardiovascular Center, Onze Lieve Vrouwziekenhuis, Hospital, Aalst, Belgium.
700    1_
$a Vijgen, Johan M $u Hasselt Heart Center, Jessa Hospital, Hasselt, Belgium.
700    1_
$a Bulava, Alan $u Department of Cardiology, Ceske Budejovice Hospital, Faculty of Health and Social Sciences, University of South Bohemia in Ceske Budejovice, Ceske Budejovice, Czech Republic.
700    1_
$a Duytschaever, Mattias, $u Department of Cardiology, Algemeen Ziekenhuis Sint Jan, Bruges, Belgium. $d 1970- $7 xx0257832
700    1_
$a Martinek, Martin $u Department of Cardiology, Ordensklinikum Linz Elisabethinen, Linz, Austria.
700    1_
$a Natale, Andrea $u Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas.
700    1_
$a Knecht, Sebastien $u Department of Cardiology, Algemeen Ziekenhuis Sint Jan, Bruges, Belgium.
700    1_
$a Neuzil, Petr $u Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic.
700    1_
$a Pürerfellner, Helmut $u Department of Cardiology, Ordensklinikum Linz Elisabethinen, Linz, Austria.
773    0_
$w MED00193518 $t JACC. Clinical electrophysiology $x 2405-5018 $g Roč. 5, č. 7 (2019), s. 778-786
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31320006 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210304151844 $b ABA008
999    __
$a ok $b bmc $g 1609221 $s 1120066
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 5 $c 7 $d 778-786 $e 20190508 $i 2405-5018 $m JACC. Clinical electrophysiology $n JACC Clin Electrophysiol $x MED00193518
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...